In Protocol 2, the investigators will determine the role of pancreatic hormones (increase in plasma glucagon and decrease in plasma insulin concentration) in the stimulation of EGP following SGLT2 inhibition.
The inhibition of the renal (kidney) SGLT2 transporter has proven to be an effective therapeutic intervention to reduce plasma glucose levels (amount of glucose found in the liquid part of blood) and HbA1c. In this study, the investigators hope to define the role of increased plasma glucagon, decline in plasma insulin, and fall in plasma glucose concentration. The investigators will examine whether the signal for the increase in EGP (endogenous glucose production) caused by glucosuria (an excess of sugar in the urine, typically associated with diabetes) is mediated via the decrease in plasma glucose and insulin concentrations, or by the increase in plasma glucagon concentration.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
30
SGLT2 inhibitor (dapagliflozin)
Placebo Comparator
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Change in Plasma Glucose Concentration
Change from baseline to the last hour of the study (240-300 minutes) in plasma glucose concentration
Time frame: Baseline to 240-300 minutes
Change in Endogenous Glucose Production (EGP)
The change in endogenous glucose production is measured from baseline until the last hour of the study
Time frame: Baseline to 240-300 minutes
Change in Plasma Insulin During Measurement of EGP
Measurement of change in plasma insulin concentration during measurement of of EGP from baseline to last hour of the study
Time frame: Baseline to 240-300 minutes
Change in Glucagon During EGP Measurement
Measurement of change in glucagon during EGP measurement from baseline to the last hour of the study
Time frame: Baseline to 240-300 minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.